RecruitingPhase 2NCT06810804

A Phase IIa Study to Evaluate NBQ72S

A Phase IIa Study to Evaluate the Efficacy and Safety of NBQ72S in Breast Cancer Patients With Leptomeningeal Metastases, With or Without Brain Parenchymal Metastases

Sponsor

Nantong Bencao Quadriga Medical Technology Co. Ltd.

Enrollment

10 participants

Start Date

Apr 22, 2025

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

A phase IIa, single-arm, open-label study was conducted to evaluate the efficacy and safety of NBQ72S, in patients with leptomeningeal metastases from breast cancer. All patients will receive the study drug every 28 days until withdrawal from treatment.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This Phase 2a study is testing a new drug called NBQ72S for breast cancer that has spread to the lining of the brain and spinal cord (called leptomeningeal metastasis). This is an extremely serious complication where cancer cells travel through the cerebrospinal fluid. **You may be eligible if...** - You have breast cancer that has spread to the leptomeninges (brain/spinal cord lining), confirmed by MRI or spinal fluid testing - Your functional status score (KPS) is 60 or higher, meaning you can care for yourself - Your blood counts are adequate (enough white cells, platelets, and hemoglobin) - You have had prior treatment for breast cancer (there is no restriction on duration) **You may NOT be eligible if...** - You cannot meet the minimum blood count thresholds - Your general health (KPS) is below 60 - You have other serious conditions that would make study participation unsafe Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.